CRT promotes maturation of APCs, cross‐presentation of tumour antigens and facilitates recruitment of Teffs, primarily CD8 cytotoxic T cells, that provide a robust immune response to tumours (Figure 4B). The gene discussed is CD8A; the disease is neoplasm.